Keros Therapeutics reported a net income of $148.5 million for the first quarter of 2025, a substantial increase from a net loss of $43.1 million in the same period last year. This growth was largely driven by revenue recognized from a license agreement with Takeda Pharmaceuticals U.S.A., Inc. The company also reported an increase in research and development expenses as it continues to advance its pipeline.

Keros Therapeutics reported a net loss of $46.0 million for the fourth quarter of 2024, an increase from the $40.2 million net loss in the same period last year. Revenue for the quarter was $3.0 million, primarily from a milestone achievement. The company's cash position was strengthened by a $200.0 million upfront payment from a license agreement with Takeda, extending its cash runway into 2029.

Keros Therapeutics reported a net loss of $53.0 million for the third quarter of 2024, driven by increased research and development expenses. The company's cash and cash equivalents as of September 30, 2024, were $530.7 million, which is expected to fund operations into the third quarter of 2027.

Keros Therapeutics reported a net loss of $45.3 million for the second quarter of 2024, compared to a net loss of $37.5 million for the same period in 2023. The increase in net loss was primarily due to increased research and development expenses.

Keros Therapeutics reported a net loss of $43.1 million for the first quarter of 2024, compared to a net loss of $35.8 million for the same period in 2023. The increase in net loss was primarily due to increased research and development expenses and general and administrative expenses. Cash and cash equivalents totaled $442.4 million as of March 31, 2024.

Keros Therapeutics reported a net loss of $40.2 million for the fourth quarter of 2023, driven by increased research and development expenses and investments to support clinical and corporate goals. The company's cash and cash equivalents totaled $331.1 million as of December 31, 2023, which, along with proceeds from a January 2024 offering, is expected to fund operations into 2027.

Keros Therapeutics reported a net loss of $39.4 million for the third quarter of 2023. Research and development expenses increased to $34.1 million, and general and administrative expenses were $9.1 million. Cash and cash equivalents totaled $287.9 million as of September 30, 2023, expected to fund operations into the fourth quarter of 2025.

Keros Therapeutics reported a net loss of $37.5 million in the second quarter of 2023, compared to a net loss of $27.3 million in the second quarter of 2022. The increase was primarily due to increased research and development efforts and additional investments to support the company's clinical and corporate goals. Keros' cash and cash equivalents as of June 30, 2023, were $322.0 million, and the company expects this to fund operations into the fourth quarter of 2025.

Keros Therapeutics reported a net loss of $35.8 million in the first quarter of 2023, compared to a net loss of $24.2 million in the first quarter of 2022. The company's cash and cash equivalents totaled $351.4 million as of March 31, 2023.

Keros Therapeutics reported a net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022. The increase in net loss for the fourth quarter and the increase in net loss for the year was largely due to increased research and development efforts, including the progression of the Company's two Phase 2 clinical trials in KER-050, one in patients with MDS and one in patients with myelofibrosis, plus an upfront payment from the Company's license agreement with Hansoh in the fourth quarter of 2021. The Company expects that its cash and cash equivalents as of December 31, 2022, together with the net proceeds from the ATM through February 28, 2023, will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2025.

Keros Therapeutics reported a net loss of $23.5 million in the third quarter of 2022. The company's cash and cash equivalents as of September 30, 2022 was $239.4 million and expects to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.

Keros Therapeutics reported a net loss of $27.3 million for the second quarter of 2022, driven by increased research and development and infrastructure expenses. The company's cash and cash equivalents totaled $215.6 million as of June 30, 2022, expected to fund operations into Q3 2024.

Keros Therapeutics reported a net loss of $24.2 million in the first quarter of 2022, compared to a net loss of $15.9 million in the first quarter of 2021. The increase in net loss was largely due to increased research and development efforts and additional infrastructure expenses.

Keros Therapeutics reported a net loss of $6.9 million for the fourth quarter and $58.7 million for the year ended December 31, 2021. Revenue for the year ended December 31, 2021 was $20.1 million. Research and development expenses were $18.8 million for the fourth quarter and $55.1 million for the year ended December 31, 2021.

Keros Therapeutics reported a net loss of $20.3 million for the third quarter of 2021, driven by increased research and development and infrastructure expenses. As of September 30, 2021, cash and cash equivalents totaled $221.3 million, expected to fund operations into the fourth quarter of 2023.

Keros Therapeutics reported a net loss of $15.6 million for the second quarter of 2021, driven by increased research and development expenses and additional infrastructure costs. The company's cash and cash equivalents were $237.1 million as of June 30, 2021, expected to fund operations into the fourth quarter of 2023.

Keros Therapeutics reported a net loss of $15.9 million in the first quarter of 2021, compared to a net loss of $11.9 million in the first quarter of 2020. The increase in net loss was primarily due to increased research and development efforts and infrastructure to support operations as a publicly traded company. Cash and cash equivalents were $255.2 million as of March 31, 2021.

Keros Therapeutics reported a net loss of $10.7 million for the fourth quarter and $45.4 million for the year ended December 31, 2020. The increase in net loss for the fourth quarter and the year was largely due to increased research and development efforts as well as the infrastructure to support operations as a publicly traded company. Keros’ cash and cash equivalents as of December 31, 2020 was $265.9 million.

Keros Therapeutics reported a net loss of $12.0 million in the third quarter of 2020. Research and development expenses were $8.4 million, and general and administrative expenses were $3.6 million. Cash and cash equivalents as of September 30, 2020, were $133.8 million.

Keros Therapeutics reported a net loss of $10.8 million in the second quarter of 2020. With the net proceeds from the IPO and earlier Series C financing, Keros believes it is well capitalized to continue to aggressively drive the development of its lead programs through multiple Phase 2 clinical trials planned for the near term.

Keros Therapeutics reported a net loss of $11.9 million in the first quarter of 2020, driven by increased research and development expenses and investments related to becoming a publicly traded company. The company's cash and cash equivalents were $54.5 million as of March 31, 2020, which doesn't include the $99.8 million net proceeds from their April 2020 IPO.